PsychoGenics and Cephalon expect to jointly identify drug candidates suitable for clinical development. If Cephalon develops clinical candidates, PsychoGenics will receive milestone payments as well as royalties. If PsychoGenics undertakes further development, it will make milestone and royalty payments to Cephalon.
Dr Emer Leahy, president and CEO of PsychoGenics, said: “We are delighted to partner with Cephalon and look forward to a successful collaboration. We are confident that combining Cephalon’s and PsychoGenics’ complementary strengths and expertise will enable us to identify a new generation of treatments for neuropsychiatric disorders.”